Celltrion applies for biosimilar infliximab approval in Japan

Biosimilares/Novedades | Posted 13/09/2013 post-comment0 Post your comment

On 11 September 2013, South Korean biotechnology company Celltrion announced that it had filed for approval of Remsima, its biosimilar infliximab monoclonal antibody, with Japan’s Ministry of Health, Labour and Welfare (MHLW).

Infliximab V13I13

The approval will be based on a clinical trial, which Celltrion conducted in Japan with its partner company, Nippon Kayaku, and which was completed in July 2013.

Remsima is a biosimilar of Johnson & Johnson’s rheumatoid arthritis blockbuster Remicade (infliximab). Remicade is the most successful tumour necrosis factor (TNF) inhibitor treatment in terms of market share in Japan, with sales of the drug in 2012 of Yen 90 billion. Japan is the second largest market for Remicade following the US.

According to an official from Nippon Kayaku ‘the Japanese approval for Remsima will be good news, not only for patients in Japan who previously had limited access to advanced therapeutics, but also for their families and their healthcare providers.’

Celltrion has already gained approval for Remsima from EMA, as well as from the Korean Ministry of Food and Drug Safety (MFDS, formerly the Korea Food and Drug Administration) [1, 2]. As Remsima has already successfully received approval from EMA, the approval process in Japan is expected to proceed smoothly.

Celltrion expects sales of Remsima in Europe to begin as early as September 2013, with the Japanese launch expected to fall in 2014, as the Japanese approval procedure usually takes around a year.

Related article

EC approves first monoclonal antibody biosimilar


1.  GaBI Online - Generics and Biosimilars Initiative. Biosimilar monoclonal antibody approved in Korea [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Sep 13]. Available from: www.gabionline.net/Biosimilars/News/Biosimilar-monoclonal-antibody-approved-in-Korea

2.  GaBI Online - Generics and Biosimilars Initiative. EMA approves first monoclonal antibody biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Sep 13]. Available from: www.gabionline.net/Biosimilars/News/EMA-approves-first-monoclonal-antibody-biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: Celltrion

comment icon Comments (0)
Post your comment
Related content
Canadá aprueba tres biosimilares más en 2022
Health Canada V13I20
Biosimilares/Novedades Posted 28/05/2024
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010